We’re obsessed with “rejuvenating” the aged heart, pouring billions into molecular reprogramming, niche mobilization, and synthetic ligands in hopes of flipping a switch to restore a youthful proteostatic state. Meanwhile, we’re ignoring the structural debt piling up in the interstitium.

In my lab, we spend our days staring at myofibroblasts that just won’t die. These aren’t just senescent cells; they’re biological squatters. A healthy heart launches a repair program after an injury, but in an aging heart, that process stalls. The myofibroblasts linger, secreting a stiff, cross-linked ECM that acts as a physical barrier to the very repair signaling we’re trying to force into the tissue.

It’s like trying to renovate a house while the previous tenants have nailed themselves to the floorboards. We’re dumping high-tech, expensive longevity interventions into a system choked by its own debris.

The myofibroblast “zombie” problem is the biggest hurdle to diastolic recovery. We don’t need another generic longevity clock to tell us the heart is old; we need a targeted, pharmacological clearance mechanism that can tell the difference between homeostatic tissue-resident fibroblasts and these persistent, fibrotic squatters.

Funding agencies keep prioritizing high-level, systemic pathways—the “sexier” longevity targets—while the visceral reality of fibrotic sequestration stays chronically under-resourced. Why are we trying to rejuvenate a substrate that is essentially entombed?

If we want to move the needle on heart failure, we’ve got to stop romanticizing the restorative potential of the aging heart until we can actually perform a metabolic and structural audit. We need to distinguish between simple biological wear-and-tear and this active, pathological persistence.

I’m looking for collaborators who realize that longevity isn't just about turning the clock back—it’s about taking out the trash. If we can’t clear these mechanical constraints, no amount of NAD+ or mitochondrial biogenesis will save the aging myocardium from its own architecture.

It’s time we pivot our grants toward ECM-degrading targeted therapies. Are we content to keep funding the dream of rejuvenation while the heart hardens into a monument to our own lack of focus?